Kaul Sanjay, Diamond George A
Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.
Curr Atheroscler Rep. 2008 Oct;10(5):398-404. doi: 10.1007/s11883-008-0062-7.
A meta-analysis of 42 clinical trials suggested that rosiglitazone, a widely used thiazolidinedione, was associated with a 43% greater risk of myocardial infarction (P = 0.03) and a 64% greater risk of cardiovascular death (P = 0.06). However, a number of criticisms have been raised that potentially undermine the conclusions of this analysis. In this article, we point out some of these limitations, summarize the currently available evidence concerning rosiglitazone and cardiovascular risk, share implications for drug safety evaluation, and offer practical recommendations to health care providers. We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone are inconclusive.
一项对42项临床试验的荟萃分析表明，广泛使用的噻唑烷二酮类药物罗格列酮与心肌梗死风险增加43%（P = 0.03）以及心血管死亡风险增加64%（P = 0.06）相关。然而，有人提出了一些批评，这些批评可能会削弱该分析的结论。在本文中，我们指出了其中一些局限性，总结了目前关于罗格列酮与心血管风险的现有证据，分享了对药物安全性评估的启示，并为医疗保健提供者提供了实用建议。我们得出结论，显示服用罗格列酮的糖尿病患者心肌梗死和心血管疾病死亡风险增加的数据尚无定论。
